Document Detail


Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure).
MedLine Citation:
PMID:  20883926     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: The purpose of this study was to determine whether coenzyme Q₁₀ is an independent predictor of prognosis in heart failure.
BACKGROUND: Blood and tissue concentrations of the essential cofactor coenzyme Q₁₀ are decreased by statins, and this could be harmful in patients with heart failure.
METHODS: We measured serum coenzyme Q₁₀ in 1,191 patients with ischemic systolic heart failure enrolled in CORONA (Controlled Rosuvastatin Multinational Study in Heart Failure) and related this to clinical outcomes.
RESULTS: Patients with lower coenzyme Q₁₀ concentrations were older and had more advanced heart failure. Mortality was significantly higher among patients in the lowest compared to the highest coenzyme Q₁₀ tertile in a univariate analysis (hazard ratio: 1.50, 95% confidence interval: 1.04 to 2.6, p = 0.03) but not in a multivariable analysis. Coenzyme Q₁₀ was not an independent predictor of any other clinical outcome. Rosuvastatin reduced coenzyme Q₁₀ but there was no interaction between coenzyme Q₁₀ and the effect of rosuvastatin.
CONCLUSIONS: Coenzyme Q₁₀ is not an independent prognostic variable in heart failure. Rosuvastatin reduced coenzyme Q₁₀, but even in patients with a low baseline coenzyme Q₁₀, rosuvastatin treatment was not associated with a significantly worse outcome. (Controlled Rosuvastatin Multinational Study in Heart Failure [CORONA]; NCT00206310).
Authors:
John J V McMurray; Peter Dunselman; Hans Wedel; John G F Cleland; Magnus Lindberg; Ake Hjalmarson; John Kjekshus; Finn Waagstein; Eduard Apetrei; Vivencio Barrios; Michael Böhm; Gabriel Kamenský; Michel Komajda; Vyacheslav Mareev; John Wikstrand;
Related Documents :
20024636 - Biomarkers in heart failure--better than history or echocardiography?
16740226 - Is oocyte morphology prognostic of embryo developmental potential after icsi?
6837606 - Cardiac failure in addison's disease.
16340936 - Myocardial disease, anemia, and erythrocyte-stimulating proteins in chronic kidney dise...
18381186 - Predischarge qrs score and risk for heart failure after first st-elevation myocardial i...
11967826 - Angiotensin ii binding and extracellular matrix remodelling in a rat model of myocardia...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  56     ISSN:  1558-3597     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-10-04     Completed Date:  2010-10-22     Revised Date:  2011-05-16    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1196-204     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Affiliation:
BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, United Kingdom. john.mcmurray@glasgow.ac.uk
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00206310
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Biological Markers / blood
Female
Fluorobenzenes / adverse effects,  therapeutic use*
Follow-Up Studies
Heart Failure / blood*,  diagnosis,  drug therapy*
Hospitalization / trends
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects,  therapeutic use*
Internationality
Male
Middle Aged
Prospective Studies
Pyrimidines / adverse effects,  therapeutic use*
Sulfonamides / adverse effects,  therapeutic use*
Treatment Outcome
Ubiquinone / analogs & derivatives*,  antagonists & inhibitors,  blood
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Fluorobenzenes; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyrimidines; 0/Sulfonamides; 1339-63-5/Ubiquinone; 287714-41-4/rosuvastatin; 303-98-0/coenzyme Q10
Comments/Corrections
Comment In:
J Am Coll Cardiol. 2011 Apr 5;57(14):1569; author reply 1569   [PMID:  21453843 ]
J Am Coll Cardiol. 2010 Oct 5;56(15):1205-6   [PMID:  20883927 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary ...
Next Document:  Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.